Dr. Reddy's, Torrent Pharma and Laurus Synthesis all land Form 483 letters following FDA inspections
03 Jan 2024
In December the FDA hit India-based Torrent Pharmaceuticals, Laurus Synthesis and Dr. Reddy’s Laboratories each with Form 483 letters published on Dec. 28. This was Dr. Reddy’s second letter in just two months.
In the latest 12-page letter for Dr. Reddy’s site located at Telangana, India, the FDA noted in detail three observations found between Dec. 4 and Dec. 8. The first Form 483 for the generic drug giant followed an inspection in October for a different unit.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.